Fortress Biotech Competitors

Fortress Biotech (NASDAQ:FBIO) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Fortress Biotech and Amgen, as reported by MarketBeat.

Fortress Biotech presently has a consensus target price of $10.75, suggesting a potential upside of 160.92%. Amgen has a consensus target price of $261.0476, suggesting a potential upside of 2.09%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Amgen.

Valuation and Earnings

This table compares Fortress Biotech and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fortress Biotech and Amgen's net margins, return on equity and return on assets.

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Institutional & Insider Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amgen beats Fortress Biotech on 9 of the 14 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Fortress Biotech and Gilead Sciences, as reported by MarketBeat.

Fortress Biotech presently has a consensus target price of $10.75, suggesting a potential upside of 160.92%. Gilead Sciences has a consensus target price of $97.92, suggesting a potential upside of 46.43%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Gilead Sciences.

Valuation and Earnings

This table compares Fortress Biotech and Gilead Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fortress Biotech and Gilead Sciences' net margins, return on equity and return on assets.

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Institutional & Insider Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 0.1% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Gilead Sciences beats Fortress Biotech on 9 of the 14 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Fortress Biotech and Vertex Pharmaceuticals, as reported by MarketBeat.

Fortress Biotech presently has a consensus target price of $10.75, suggesting a potential upside of 160.92%. Vertex Pharmaceuticals has a consensus target price of $293.1250, suggesting a potential upside of 33.61%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Vertex Pharmaceuticals.

Valuation and Earnings

This table compares Fortress Biotech and Vertex Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fortress Biotech and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Institutional & Insider Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Fortress Biotech on 11 of the 15 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Institutional & Insider Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Fortress Biotech and Regeneron Pharmaceuticals, as reported by MarketBeat.

Fortress Biotech presently has a consensus target price of $10.75, suggesting a potential upside of 160.92%. Regeneron Pharmaceuticals has a consensus target price of $646.2609, suggesting a potential upside of 28.58%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Fortress Biotech and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Fortress Biotech and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Fortress Biotech on 10 of the 15 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

32.1% of Fortress Biotech shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 29.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Fortress Biotech and Biogen, as reported by MarketBeat.com.

Fortress Biotech presently has a consensus price target of $10.75, suggesting a potential upside of 160.92%. Biogen has a consensus price target of $303.5862, suggesting a potential upside of 12.31%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Biogen.

Earnings & Valuation

This table compares Fortress Biotech and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares Fortress Biotech and Biogen's net margins, return on equity and return on assets.

Summary

Biogen beats Fortress Biotech on 9 of the 14 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

32.1% of Fortress Biotech shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 29.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Fortress Biotech and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Fortress Biotech presently has a consensus price target of $10.75, suggesting a potential upside of 160.92%. Alexion Pharmaceuticals has a consensus price target of $153.8636, suggesting a potential downside of 6.00%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Fortress Biotech and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Profitability

This table compares Fortress Biotech and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats Fortress Biotech on 9 of the 15 factors compared between the two stocks.